{"version":"1.0","provider_name":"Frezza Partners","provider_url":"https:\/\/frezzapartners.com\/en\/","author_name":"Frezza Partners","author_url":"https:\/\/frezzapartners.com\/en\/author\/fr3zz4partn3rs\/","title":"Nomine - Gennaio 2019 - Frezza Partners","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ewMrSAwxcX\"><a href=\"https:\/\/frezzapartners.com\/en\/magazine\/nomine-gennaio-2019\/\">Nomine &#8211; Gennaio 2019<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/frezzapartners.com\/en\/magazine\/nomine-gennaio-2019\/embed\/#?secret=ewMrSAwxcX\" width=\"600\" height=\"338\" title=\"&#8220;Nomine &#8211; Gennaio 2019&#8221; &#8212; Frezza Partners\" data-secret=\"ewMrSAwxcX\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/frezzapartners.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/frezzapartners.com\/wp-content\/uploads\/2019\/02\/the-creative-exchange-713137-unsplash-e1550155628305.jpg","thumbnail_width":1500,"thumbnail_height":1125,"description":"photo by The Creative Exchange Daniel O\u2019Day, oggi in Roche, sar\u00e0 nominato CEO di Gilead Sciences a partire dal 1\u00b0 marzo 2019. Prender\u00e0 il posto di John Milligan, che aveva gi\u00e0 dichiarato l\u2019addio lo scorso luglio. In attesa dell\u2019entrata di O\u2019Day, la company americana ha annunciato che in questi mesi il ruolo sar\u00e0 affidato ad interim a Gregg Alton, da agosto 2018 Chief Patient Officer di Gilead. Susanne Schaffert \u00e8 il nuovo CEO della divisione oncologia di Novartis. Ne ha..."}